About Natco Pharma Limited
Data last updated: 22 December 2025
Natco Pharma Limited is a public limited company based in Hyderabad, Telangana, India. It specialises in fertilizers and soil enhancers, a part of the broader agriculture sector. Incorporated on 19 September 1981, the company has been in operation for over 45 years.
Registered with ROC Hyderabad under CIN L24230AP1981PLC003201. Listed on BSE: 524816 and NSE: NATCOPHARM.
Capital: an authorised share capital of ₹45 Cr and a paid-up capital of ₹35.82 Cr. Formerly known as Natco Fine Pharmaceuticals Private Limited. It is led by directors including Lakshminarayana Bolisetty and Rajeev Nannapaneni.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Natco House Road No.2 Banjara Hills, Hyderabad, Telangana, India – 500034.
As per the financials filed for FY 2025, the company reported a revenue of ₹4,784 Cr, a growth of 16% compared to the previous year.
The company has a workforce of approximately 4,652 employees as per the latest available data.
The company is associated with 1 brand - Natco Pharma. As per MCA filings, the company has open charges of ₹1,120 Cr and satisfied charges of ₹1,277.71 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website natcopharma.co.in.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressNatco House Road No.2 Banjara Hills, Hyderabad, Telangana, India – 500034
-
IndustryAgriculture, Fertilizers & Soil Enhancers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Natco Pharma Limited
Natco Pharma Limited has one previous CIN (Corporate Identification Number): L24230AP1981PLC003201. The current CIN is L24230TG1981PLC003201, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230TG1981PLC003201 | Current |
| L24230AP1981PLC003201 | Previous |
Associated Brands with Natco Pharma Limited
Natco Pharma Limited operates one associated brand: Natco Pharma. These brands represent Natco Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| APIs and finished dosage forms are developed and manufactured. | natcopharma.co.in |
Business Activity of Natco Pharma Limited
Natco Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Natco Pharma Limited
Natco Pharma Limited is currently managed by 11 directors, with 26 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Lakshminarayana Bolisetty
Also directs:
B.N. Rathi Securities Limited, B2b Software Technologies Limited, Mahathi Infra Services Private Limited and 1 more
|
Director | 12 Aug 2024 | 1 Years 10 Months | Current |
|
Rajeev Nannapaneni
Also directs:
Natco Aqua Limited, Natsoft Information Systems Private Limited, L V P Eye Innovations Foundation and 1 more
|
Whole-Time Director | 01 Jun 2012 | 14 Years 1 Months | Current |
| Vijayabhaskar Dronadula | Director | 01 Apr 2024 | 2 Years 3 Months | Current |
|
Nitin Rameshwar Jain
Also directs:
Amanta Healthcare Limited
|
Director | 12 Aug 2024 | 1 Years 10 Months | Current |
|
Potluri Prasad Sivaramakrishna
Also directs:
Natco Crop Health Sciences Limited
|
Whole-Time Director | 12 Nov 2014 | 11 Years 7 Months | Current |
| Venkaiah Chowdary Nannapaneni | Managing Director | 01 Apr 2015 | 11 Years 3 Months | Current |
Financials of Natco Pharma Limited FY 2024 filings available
Natco Pharma Limited reported revenue of ₹4,784 Cr (up 16% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Natco Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Jul 2025 | State Bank of India | ₹600 Cr | Open |
| 08 Mar 2011 | Others | ₹520 Cr | Open |
| 18 Oct 2016 | Others | ₹50 Cr | Satisfied |
| 22 Jun 2015 | Citi Bank N.A. | ₹12.05 Cr | Satisfied |
| 22 Dec 2014 | Citi Bank N.A. | ₹60 Cr | Satisfied |
Total charge records: 58 View all charges
Employees and EPFO Compliance at Natco Pharma Limited
View historical data on people associated with Natco Pharma Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Natco Pharma Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Natco Pharma Limited
GSTIN & GST Filing Data of Natco Pharma Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Natco Pharma Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Natco Pharma Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Natco Pharma Limited
MSME Payment Delays by Natco Pharma Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Natco Pharma Limited
Subsidiaries & Group Companies of Natco Pharma Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Natco Pharma Limited with ownership details.
MCA Filings & Documents of Natco Pharma Limited
MCA Filings & Documents of Natco Pharma Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Natco Pharma Limited
Recent News on Natco Pharma Limited
Frequently Asked Questions about Natco Pharma Limited
Natco Pharma Limited is an active public limited company in the agriculture sector based in Hyderabad, Telangana, India. It was incorporated on 19 September 1981 (45+ years old) and is registered under CIN L24230TG1981PLC003201. Listed on BSE: 524816 and NSE: NATCOPHARM. The company has 4,652 employees.
Natco Pharma Limited reported revenue of ₹4,784 Cr for FY 2025 (up 16.00% YoY).
The current directors of Natco Pharma Limited are:
- Lakshminarayana Bolisetty
- Rajeev Nannapaneni
- Vijayabhaskar Dronadula
- Venkat Ramesh Chekuri
- Nitin Rameshwar Jain
- Potluri Prasad Sivaramakrishna
- Venkaiah Chowdary Nannapaneni
- Agnihotra Dakshina Murty Chavali
- Kantipudi Suma
- Lingarao Donthineni
- Veera Venkata Narasimha Appa Rao Sannidhanam
The primary industry of Natco Pharma Limited is agriculture. The company specifically operates in fertilizers and soil enhancers. The company is currently active in this sector.
Yes. Natco Pharma Limited is listed on both BSE (code: 524816) and NSE (symbol: NATCOPHARM).
Natco Pharma Limited can be reached at the registered office: Natco House Road No.2 Banjara Hills, Hyderabad, Telangana, India – 500034, or through the website natcopharma.co.in.